The relationship between hemoglobin variability and oxidative stress and inflammation in CKD

DOI: 10.4328/JCAM.5912 Received: 26.05.2018 Accepted: 09.06.2018 Published Online: 10.06.2018 Printed: 01.01.2019 J Clin Anal Med 2019;10(1): 20-5 Corresponding Author: Tulay Kus, Department of Medical Oncology, Adıyaman University, Training and Research Hospital, TR-02040, Adıyaman, Turkey. T.: +90 4162161015 F.: +90 4162161014 E-Mail: drtulaykus83@hotmail.com Abstract Aim: Hemoglobin (Hg) variability, which is frequently seen in patients with chronic kidney disease (CKD) who undergo dialysis, has been shown to be associated with increased mortality and cardiovascular disease (CVD) , but its mechanism remains unclear. Increased oxidative stress and inflammation with uremia lead to the development of anemia. In this context, we aimed to investigate the relationship between Hb variability and oxidative stress and inflammation. Material and Method: The data of 114 patients followed by dialysis service of Gaziantep University were included in this study retrospectively. Myeloperoxidase (MPO), nitrotyrosine (NTY), total antioxidant capacity (TAC), interleukin-6 (IL-6), Hs-CRP, and plasminogen activator inhibitor-1(PAI-1) levels of the patients whom we divided into 6 groups according to their Hg variability were measured. A control group (n = 30) was also formed demographically and clinically appropriate to this group. Results: The mean MPO, NTY, IL-6, Hs-CRP, and PAI-1 levels were higher in the dialysis patients than in the control group, whereas TAC levels were lower. Prooxidant, inflammation and procoagulant activity levels were lower in the Group 6 (Hg>12) and the Group 3 (stable, Hg=11-12 gr/dl) but higher in wide Hg variable group (Group 5) and Group 1 (Hg <12 gr/dl). Discussion: Oxidative stress, inflammation, and procoagulant activity, which are associated with higher CVD and mortality were found to be high in wide Hg variable and anemic groups in patients who underwent dialysis. The present study has a valuable finding in terms of elucidating the possible mechanism of increased mortality in patients with wide variable Hg course.

[1]  Connie M. Rhee,et al.  Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis , 2017, American Journal of Nephrology.

[2]  D. Gilbertson,et al.  Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study
 , 2017, Clinical nephrology.

[3]  W. Fang,et al.  The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study , 2017, International Urology and Nephrology.

[4]  Tetsuhiro Tanaka,et al.  How the Target Hemoglobin of Renal Anemia Should Be? , 2015, Nephron.

[5]  R. Foley,et al.  Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  R. Foley,et al.  Hemoglobin level variability: associations with mortality. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[7]  M. Joffe,et al.  Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.

[8]  R. Foley,et al.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[9]  S. Greenland,et al.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  S. Fishbane,et al.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.

[11]  J. Lazarus,et al.  Effect of variability in anemia management on hemoglobin outcomes in ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  P. Stenvinkel,et al.  Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  A. Hishida,et al.  Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. , 2002, Kidney international.

[14]  P. Stenvinkel,et al.  Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  Z. Massy,et al.  Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  B. Babior The NADPH Oxidase of Endothelial Cells , 2000, IUBMB life.